



BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

11/12, Sector-E, Sanwer Road, Industrial Area, Indore- 452 015. Fax : 0731-2723017
Tel. : 0731 - 2723016, 4066516 Email : biofilchemicals@yahoo.com
Admn. Office : B-12/B, Industrial Estate, Pologround, Indore - 452 015 (M.P.)
Tel. : 0731-4011700, 2420926, 2424003, 2423435 Fax : 4011740

To
The Secretary,
The National Stock Exchange of India Limited
Bandra Kurla Complex
Mumbai

To
The Secretary,
The Bombay Stock Exchange Limited
P.J. Tower, Dalal Street
Mumbai

Dated: 10th February, 2014

Dear Sir,

Sub: Outcome of Board meeting held on 10.02.2014 for approve Un-audited Financial Results along with limited review report for the quarter ended on 31st December, 2013.

With reference to the above-mentioned subject in meeting of the Board of the Directors of the Company held on today, the Board of the directors take on record and approve the Un-audited Financial Results of the Company for the quarter ended on 31st December, 2013 along with limited review report on quarterly financial statements of the company given by Statutory auditor of the company.

Copy of Results and Limited Review report is enclosed with letter for your information and records

Please find the same and oblige.

Thanking you,

Yours Faithfully
For Biofil Chemicals & Pharmaceuticals Ltd.

(Managing Director)

Encl : a/a

Un-Audited Financial Results of Quarter Ended Dec . 2013
31-12-2013 of M/s. Biofil Chemicals & Pharmaceuticals Limited
11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)

Un-AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31st December , 2013

Rs. In Lacs

PART I		(Rs. in Lakhs)					
	Particulars	Quarter Ended			Half Year Ended		Year Ended
		3 Months ended	Corresponding 3 Months ended	Preceding 3 Months ended	9 Months Ended	9 Months Ended	Twelve Months ended
		31.12.2013	31.12.2012	30.09.2013	31.12.2013	31.12.2012	31.03.2013
	(Refer Notes Below)	Revised	Revised	Revised	Revised	Revised	(Audited)
1	Income from operations						
	(a) Net sales/ income from operations (Net of Excise duty)	196.76	75.77	91.17	375.64	262.38	439.65
	(b) Other operating income	115.56	3.41		115.56	9.24	161.43
	Total income from operations (net)	312.32	79.18	91.17	491.20	271.62	601.09
2	Expenses						
	(a) Cost of materials consumed	26.64	21.68	61.54	139.90	85.36	159.30
	(b) Purchases of stock-in-trade	157.31	45.42	20.86	201.89	144.43	240.97
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(2.22)	(4.05)	(13.25)	(27.72)	(16.36)	(24.73)
	(d) Employee benefits expense	4.36	2.55	6.02	16.68	9.27	43.39
	(e) Depreciation and amortisation expense	5.27	4.76	5.25	15.77	14.30	21.10
	(f) Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	77.36	3.92	5.22	88.29	18.67	81.08
	Total expenses	268.72	74.26	85.64	434.80	255.66	521.11
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	43.59	4.92	5.53	56.39	15.96	79.98
4	Other income	1.05	1.05	1.05	3.15	3.15	6.20
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	44.64	5.97	6.58	59.54	19.11	86.17
6	Finance costs	3.75	2.45	3.75	11.25	7.05	19.16
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 + 6)	40.89	3.52	2.83	48.29	12.06	67.01
8	Exceptional items						
9	Profit / (Loss) from ordinary activities before tax (7 + 8)	40.89	3.52	2.83	48.29	12.06	67.01
10	Tax expense						12.77
11	Net Profit / (Loss) from ordinary activities after tax (9 + 10)	40.89	3.52	2.83	48.29	12.06	54.24
12	Minority interest *						
13	Net profit/(loss) after taxes minority interest and share of profit/ (loss) of associates (13+14+ 15)	40.89	3.52	2.83	48.29	12.06	54.24
14	Paid-up equity share capital	1627.38	1627.38	1627.38	1627.38	1627.38	1627.38
	(Face Value of the Share shall be indicated)	10	10	10	10	10	10
15	Reserve excluding Revaluation Reserves						-1274.37
16.i	Earnings per share (before extraordinary items)						
	(of Rs. 10/- each) (not annualised):						
	(a) Basic	0.0251	0.0022	0.0017	0.0297	0.0074	0.0333
	(b) Diluted						

See accompanying note to the financial results

PART II

	Particulars	3 Months ended	Corresponding 3 Months ended	Preceding 3 Months Ended	9 Months Ended	9 Months Ended	Twelve Months ended
		31.12.2013	31.12.2012	30.09.2013	31.12.2013	31.12.2012	31.03.2013
		Revised	Revised	Revised	Revised	Revised	(Audited)
A	PARTICULARS OF SHAREHOLDING						
1	Public shareholding						
	- Number of shares	8655100	8655100	8655100	8655100	8655100	8655100
	- Percentage of shareholding	53.18	53.18	53.18	53.18	53.18	53.18
2	Promoters and Promoter Group Shareholding **						
	a) Pledged / Encumbered	Nil	Nil	Nil	Nil	Nil	Nil
	- Number of shares	Nil	Nil	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil	Nil
	b) Non - encumbered						
	- Number of shares	7618700	7618700	7618700	7618700	7618700	7618700
	- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	100	100	100	100	100	100
	- Percentage of shares (as a % of the total share capital of the company)	46.82	46.82	46.82	46.82	46.82	46.82

	Particulars	3 months ended
B	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	Nil
	Disposed of during the quarter	Nil
	Remaining unresolved at the end of the quarter	Nil

Notes

1. Above Unaudited Financial Results were reviewed by Audit Committee and approved by Board of Directors in their meeting held on 10th February 2014
2. Figures have been regrouped wherever necessary including as per revised schedule VI
3. The Statuary auditors have carried out a limited review of the result for quarter ended 31st December 2013

Date : 10.02.2014

Place : indore

RAMESH SHAH
MANAGING DIRECTOR

BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

Segmentwise Revenue, Results and Capital Employed for half year ended 31st December 2013
(Under Clause 41 Listing Agreement)

Rs. In lacs

S.No.	Segment Revenue						
		3 Months ended	Corresponding 3 Months ended	Preceding 3 Months ended	9 Months ended	9 Months ended	Twelve Months ended
		31.12.2013	31.12.2012	30.09.2013	31.12.2013	31.12.2012	31.03.2013
		Reviewed	Reviewed	Reviewed	Reviewed	Reviewed	Audited
1	Segment Revenue						
	Pharma Unit	298.78	47.18	20.04	335.28	161.34	403.67
	Chemicals Division	26.75	23.73	46.80	129.92	81.66	147.30
	Plastic Division	(12.74)	8.28	23.84	26.00	28.62	50.11
	Other	1.05	1.05	1.05	3.15	3.15	6.12
	Gross Turnover	313.84	80.23	91.74	494.35	274.78	607.21
2	Segment Results						
	Pharma Unit	77.02	3.41	(1.23)	74.54	13.59	104.99
	Chemicals Division	(14.73)	4.09	9.27	6.36	10.11	(7.40)
	Plastic Division	(18.71)	(1.53)	(1.46)	(22.42)	(4.59)	(9.36)
	Other	1.05	0.00	0.00	1.05	0.00	(2.24)
	Total Segment Profit Before Tax	44.64	5.97	6.58	59.54	19.11	85.99
	Interest Income	-	-	-	-	-	0.08
	Interest Expenses	3.75	2.45	3.75	11.25	7.05	19.05
	Other Unallocable Income net of Expenditure						
	Profit Before Tax	40.89	3.52	2.83	48.29	12.05	67.01
	Provision for current tax	-	-	-	-	-	(12.77)
	Profit After Tax	40.89	3.52	2.83	48.29	12.05	54.24
3	Capital Employed						
	(Segment Assets- Segment Liabilities)						
	Pharma Unit	163.62	(201.61)	246.45	163.62	(201.61)	(71.87)
	Chemicals Division	582.15	740.67	554.49	582.15	740.67	661.18
	Plastic Division	(23.18)	71.16	(15.96)	(23.18)	71.16	75.31
	Other	0.00	75.25	(51.55)	0.00	75.25	84.40
	Total Capital Employed	722.60	685.47	733.42	722.60	685.47	749.02

DATE : 10-02-2014
PLACE : INDORE

BIOFIL CHEMICALS & PHARMACEUTICALS LTD.



RAMESH SHAH
MANAGING DIRECTOR

S.N. GADIYA

B. Com. F.C.A.

LIMITED REVIEW REPORT
FOR THE QUARTER ENDED ON 31st DECEMBER 2013

We have reviewed the accompanying statement of unaudited financial results of **M/S. BIOFIL CHEMICALS & PHARMACEUTICALS LTD.** for the quarter ended 31st December 2013 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S.N. Gadiya & Co.
Chartered Accountants
(Registration No. : 002052C)

Place: Indore **INDORE**
Date : 10.02.2014




(S.N.Gadiya)
Proprietor
Membership No: 71229